1. Home
  2. IFF vs INSM Comparison

IFF vs INSM Comparison

Compare IFF & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo International Flavors & Fragrances Inc.

IFF

International Flavors & Fragrances Inc.

SELL

Current Price

$80.24

Market Cap

24.0B

Sector

Industrials

ML Signal

SELL

Logo Insmed Incorporated

INSM

Insmed Incorporated

SELL

Current Price

$119.43

Market Cap

22.4B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
IFF
INSM
Founded
1833
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.0B
22.4B
IPO Year
2010
2000

Fundamental Metrics

Financial Performance
Metric
IFF
INSM
Price
$80.24
$119.43
Analyst Decision
Buy
Strong Buy
Analyst Count
20
24
Target Price
$98.24
★ $194.18
AVG Volume (30 Days)
2.4M
★ 3.5M
Earning Date
11-03-2026
10-29-2026
Dividend Yield
★ 2.00%
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.64
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$206.94
Revenue Next Year
$3.06
$60.77
P/E Ratio
$124.98
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$62.06
$90.39
52 Week High
$95.27
$212.75

Technical Indicators

Market Signals
Indicator
IFF
INSM
Relative Strength Index (RSI) 33.19 60.96
Support Level $70.55 $119.23
Resistance Level $80.59 $140.30
Average True Range (ATR) 2.45 5.30
MACD -1.23 1.85
Stochastic Oscillator 4.28 75.37

Price Performance

Historical Comparison
IFF
INSM

About IFF International Flavors & Fragrances Inc.

International Flavors & Fragrances is the largest specialty ingredients producer globally. It sells ingredients for the food, beverage, health, household goods, personal care, and pharmaceutical industries. The company makes proprietary formulations and partners with customers to deliver custom solutions. Through its taste and scent segments, which each generate around 25% of profits, IFF is a leading flavor and fragrance producer. The health and biosciences business, which generates 30% of profits, is a global leader in probiotics and enzymes. The remaining profits come from the food ingredients business, which sells texturants, plant-based proteins, and other ingredients, though IFF plans to divest it in a deal expected to close in 2027.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Share on Social Networks: